PhRMA: protect authorized generics

Share this article:

The Pharmaceutical Research and Manufacturers of America is defending industry patent settlements after an August 31 FTC report on authorized generics. PhRMA lauded the report's finding that an authorized generic is tied to lower prices for generics on the market before a 180-day market-exclusivity period's end, but added that a “potentially valuable report”  furthered an attack on patent settlements. 

“Authorized generics have not discouraged the availability of generics to patients,” the group stated. “Nearly 80% of prescriptions in the United States are already for generics, and the number of branded products facing Paragraph IV patent challenges has continued to grow.”

But FTC chairman Jon Leibowitz says  “brand companies may be using the threat of launching an authorized ge-neric as a powerful inducement for generic companies to delay bringing their drugs to market.” 

The FTC noted that more innovative drug companies are starting to market authorized generics while a generic firm is beginning its 180-day marketing exclusivity period, leading to questions about the effects of authorized generics on drug competition.

Share this article:
close

Next Article in Features

Email Newsletters

More in Features

Antidote: On Cystic Fibrosis treatments

Antidote: On Cystic Fibrosis treatments

Recent treatments in CF, including the inhaled antibiotic Tobramycin, have increased lifespan well into adulthood.

The $3 generic and the $1,000 pill: pharma outsiders just don't get it

The $3 generic and the $1,000 pill: pharma ...

What do you call the people who treat medical breakthroughs as if they were bank heists? Malicious? Uninformed? Not with it?

Leadership Exchange Uncut : The Agency-Client Relationship

Leadership Exchange Uncut : The Agency-Client Relationship

Click the above link to access MM&M's first Leadership Exchange Uncut e-book, "The Agency-Client Relationship"